I came to Genentech in 1981 from MIT as a newly minted Biochemical Engineer and was hired as a Scientist to help establish the Biocatalysis Department then in Research, and in 1987 joined Medicinal and Biomolecular Chemistry. In 1988 I moved into Fermentation R&D, developing the initial process technology for antibody fragment expression in E. coli, and from 1994 led the E. coli fermentation development labs for the next decade. Since that time I have focused on mammalian cell culture technology development, and for 12 years led a Cell Culture group in Pharma Technical Development that works to develop mammalian manufacturing cell lines and to improve cell line development, during the development of targeted integration, 1-cell bispecific antibody cell lines, pool-for-tox timeline acceleration, single cell lines for tox through production, and timeline acceleration from serum free cell line development. Titers went from 1 g/L to > 10 g/L over this period. Since 2018 I've served as a technical expert for this and other groups in Cell Culture.
Pharma Technical Development bridges Research to Manufacturing, and I enjoy tremendously the opportunity to engage the diverse problems that entails, working with ingenious people across the company.
Biotechnology Progress, ISSN: 87567938
I work with others to understand the underlying processes at work in our production processes and our process development to guide the improvement of both, and search across biology for new understandings and tools we can apply for the same purposes.